Search

Search Constraints

You searched for: Author/Creator Etienne, Gabriel

Search Results

1. A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study. (10th February 2020)

2. Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis. Issue 3 (5th June 2020)

3. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. (September 2016)

4. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. (September 2016)

5. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. (30th June 2021)

6. Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study). (10th October 2022)

7. Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency. Issue 3 (June 2018)

8. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Issue 14 (3rd May 2018)

9. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia. Issue 6 (27th April 2018)

10. ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?. Issue 1 (25th October 2014)